和黄医药：2025年业绩回顾：收入26年有望复苏；关注ATTC平台长期价值-20260307

Investment Rating - The report maintains an "Outperform" rating for Hutchmed (China) Limited with a target price of HK$38.11, reflecting a potential upside from the current price of HK$22.18 [2][25]. Core Insights - Hutchmed reported a total revenue of USD 549 million for FY25, a decrease of 13% year-on-year, with oncology/immunology combined revenue at USD 290 million, down 21% year-on-year. This decline was attributed to a high base effect from a previous milestone payment and a drop in domestic sales of key products [3][18]. - The management expects a recovery in sales for FY26, projecting oncology/immunology revenue between USD 330 million and USD 450 million, which includes potential income from licensing the ATTC platform [3][19]. - The company is focusing on the development of its Antibody-Targeted Toxin Conjugate (ATTC) platform, with two products currently in global clinical development [6][19]. Financial Performance - For FY25, Hutchmed's net profit attributable to shareholders was USD 460 million, significantly boosted by a one-time gain of USD 480 million from the sale of a subsidiary [3][18]. - R&D expenses were USD 150 million, down 30% year-on-year, while SG&A expenses were USD 100 million, a decrease of 9% year-on-year [3][18]. - The company had cash and cash equivalents of USD 1.37 billion at the end of FY25, indicating a strong liquidity position [3][18]. Product Performance - Fruquintinib (ex-China) sales reached USD 370 million, up 26% year-on-year, driven by growth in the Japanese market and improved reimbursement coverage in Europe. However, domestic sales of Fruquintinib (China) fell to USD 76.9 million, down 11% year-on-year [19][23]. - The report highlights that the sales of core products in China showed signs of improvement in the second half of FY25, with Fruquintinib (China) revenue increasing by 29% quarter-on-quarter [19][23]. Clinical Development - HMPL-A251, a first-in-class ATTC targeting HER2, has shown promising anti-tumor activity comparable to existing therapies and is currently in a global Phase I/IIa clinical trial [20][24]. - HMPL-A580, another ATTC candidate targeting EGFR, has also entered clinical development, with a global Phase I trial initiated in March 2026 [21][22]. - Management plans to submit a global clinical trial application for a third ATTC candidate, HMPL-A830, within 2026 [22].